Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00556712




Registration number
NCT00556712
Ethics application status
Date submitted
9/11/2007
Date registered
12/11/2007
Date last updated
11/02/2015

Titles & IDs
Public title
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Scientific title
A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy
Secondary ID [1] 0 0
BO18192
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - erlotinib [Tarceva]
Treatment: Drugs - Placebo

Experimental: Erlotinib - Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.

Placebo comparator: Placebo - Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.


Treatment: Drugs: erlotinib [Tarceva]
150mg po daily

Treatment: Drugs: Placebo
po daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008)
Timepoint [1] 0 0
Screening, BL [=21 days after randomization], every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Primary outcome [2] 0 0
PFS in All Participants (Data Cutoff 17 May 2008)
Timepoint [2] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Primary outcome [3] 0 0
Probable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)
Timepoint [3] 0 0
6 months
Primary outcome [4] 0 0
Percentage of Epidermal Growth Factor Receptor (EGFR) Immunohistochemistry (IHC) Positive Participants With PD or Death (Data Cutoff 17 May 2008)
Timepoint [4] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Primary outcome [5] 0 0
PFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008)
Timepoint [5] 0 0
Screening, BL (= 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Primary outcome [6] 0 0
Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive and Progression Free at 6 Months (Data Cutoff 17 May 2008)
Timepoint [6] 0 0
6 months
Secondary outcome [1] 0 0
Percentage of All Participants Who Died (Data Cutoff 12 January 2012)
Timepoint [1] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months).
Secondary outcome [2] 0 0
Overall Survival (OS) in All Participants (Data Cutoff 12 January 2012)
Timepoint [2] 0 0
Screening, BL (= 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)
Secondary outcome [3] 0 0
Probable Percentage of Participants Remaining Alive at 1 Year (Data Cutoff 12 January 2012)
Timepoint [3] 0 0
1 year
Secondary outcome [4] 0 0
Percentage of EGFR IHC Positive Participants Who Died (Data Cutoff 12 January 2012)
Timepoint [4] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)
Secondary outcome [5] 0 0
OS in EGFR IHC Positive Population (Data Cutoff 12 January 2012)
Timepoint [5] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)
Secondary outcome [6] 0 0
Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive at 1 Year (Data Cutoff 12 January 2012)
Timepoint [6] 0 0
1 year
Secondary outcome [7] 0 0
Percentage of EGFR IHC Negative Participants With PD or Death (Data Cutoff 17 May 2008)
Timepoint [7] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 71 months)
Secondary outcome [8] 0 0
PFS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008)
Timepoint [8] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [9] 0 0
Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)
Timepoint [9] 0 0
6 months
Secondary outcome [10] 0 0
Percentage of EGFR IHC Negative Participants Who Died (Data Cutoff 17 May 2008)
Timepoint [10] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [11] 0 0
OS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008)
Timepoint [11] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [12] 0 0
Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive at 1 Year (Data Cutoff 17 May 2008)
Timepoint [12] 0 0
1 year
Secondary outcome [13] 0 0
Time to Progression (Data Cutoff 17 May 2008)
Timepoint [13] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [14] 0 0
Probable Percentage of Participants Remaining Progression-Free in the TTP Analysis at 6 Months (Data Cutoff 17 May 2008)
Timepoint [14] 0 0
6 months
Secondary outcome [15] 0 0
Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST (Data Cutoff 17 May 2008)
Timepoint [15] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [16] 0 0
Percentage of Participants With a CR, PR, Stable Disease (SD), or PD According to RECIST (Data Cutoff 17 May 2008)
Timepoint [16] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [17] 0 0
Percentage of Participants With a Response Upgrade From BL According to RECIST (Data Cutoff 17 May 2008)
Timepoint [17] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [18] 0 0
Percentage of Participants With a Change of PR to CR or SD to PR or CR From BL to End of Treatment According to RECIST (Data Cutoff 17 May 2008)
Timepoint [18] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [19] 0 0
Percentage of Participants With CR, PR, or SD or With SD [Maintained For Greater Than (>) 12 Weeks] or CR or PR (Data Cutoff 17 May 2008)
Timepoint [19] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [20] 0 0
Percentage of Participants With Symptom Progression Assessed Using the Lung Cancer Subscale (LCS) (Data Cutoff 17 May 2008)
Timepoint [20] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [21] 0 0
Time to Symptom Progression (Data Cutoff 17 May 2008)
Timepoint [21] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [22] 0 0
Probable Percentage of Participants Remaining Without Symptom Progression at 6 Months (Data Cutoff 17 May 2008)
Timepoint [22] 0 0
6 months
Secondary outcome [23] 0 0
Percentage of Participants With Deterioration Assessed Using the Trial Outcome Index (Data Cutoff 17 May 2008)
Timepoint [23] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [24] 0 0
Time to Deterioration in TOI (Data Cutoff 17 May 2008)
Timepoint [24] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [25] 0 0
Probable Percentage of Participants Remaining Without Deterioration in TOI at 6 Months (Data Cutoff 17 May 2008)
Timepoint [25] 0 0
6 months
Secondary outcome [26] 0 0
Percentage of Participants With Deterioration in Quality of Life Assessed Using TOI, SWB, and EWB (Data Cutoff 17 May 2008)
Timepoint [26] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [27] 0 0
Time to Deterioration in QoL (Data Cutoff 17 May 2008)
Timepoint [27] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [28] 0 0
Probable Percentage of Participants Remaining Without Deterioration in QoL at 6 Months (Data Cutoff 17 May 2008)
Timepoint [28] 0 0
6 months
Secondary outcome [29] 0 0
Functional Assessment of Chronic Illness Therapy - Lung (FACT-L) Scores (Data Cutoff 17 May 2008)
Timepoint [29] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Secondary outcome [30] 0 0
Change From BL in FACT-L Scores (Data Cutoff 17 May 2008)
Timepoint [30] 0 0
Screening, BL (=21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)

Eligibility
Key inclusion criteria
* adult patients >=18 years of age;
* histologically documented, locally advanced , recurrent or metastatic NSCLC;
* measurable disease;
* no disease progression after 4 cycles of platinum-based chemotherapy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* unstable systemic disease;
* any other malignancies in the last 5 years.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2010
Sample size
Target
Accrual to date
Final
889
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
- St. Leonards
Recruitment hospital [2] 0 0
- Waratah
Recruitment hospital [3] 0 0
- Brisbane
Recruitment hospital [4] 0 0
- Adelaide
Recruitment hospital [5] 0 0
- East Bentleigh
Recruitment hospital [6] 0 0
- Fitzroy
Recruitment hospital [7] 0 0
- Geelong
Recruitment hospital [8] 0 0
- Melbourne
Recruitment postcode(s) [1] 0 0
2065 - St. Leonards
Recruitment postcode(s) [2] 0 0
2298 - Waratah
Recruitment postcode(s) [3] 0 0
4101 - Brisbane
Recruitment postcode(s) [4] 0 0
5041 - Adelaide
Recruitment postcode(s) [5] 0 0
VIC 3165 - East Bentleigh
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment postcode(s) [7] 0 0
3220 - Geelong
Recruitment postcode(s) [8] 0 0
3084 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Innsbruck
Country [2] 0 0
Austria
State/province [2] 0 0
Klagenfurt
Country [3] 0 0
Austria
State/province [3] 0 0
Wien
Country [4] 0 0
Belgium
State/province [4] 0 0
Antwerpen
Country [5] 0 0
Belgium
State/province [5] 0 0
Edegem
Country [6] 0 0
Canada
State/province [6] 0 0
Manitoba
Country [7] 0 0
Canada
State/province [7] 0 0
Ontario
Country [8] 0 0
Canada
State/province [8] 0 0
Quebec
Country [9] 0 0
Chile
State/province [9] 0 0
Santiago
Country [10] 0 0
China
State/province [10] 0 0
Beijing
Country [11] 0 0
China
State/province [11] 0 0
Guangzhou
Country [12] 0 0
China
State/province [12] 0 0
Shanghai
Country [13] 0 0
Czech Republic
State/province [13] 0 0
Ceské Budejovice
Country [14] 0 0
Czech Republic
State/province [14] 0 0
Olomouc
Country [15] 0 0
Czech Republic
State/province [15] 0 0
Plzen
Country [16] 0 0
Denmark
State/province [16] 0 0
Herlev
Country [17] 0 0
Denmark
State/province [17] 0 0
Odense
Country [18] 0 0
France
State/province [18] 0 0
Bayonne
Country [19] 0 0
France
State/province [19] 0 0
Brest
Country [20] 0 0
France
State/province [20] 0 0
Clermont-ferrand
Country [21] 0 0
France
State/province [21] 0 0
Dijon
Country [22] 0 0
France
State/province [22] 0 0
Le Mans
Country [23] 0 0
France
State/province [23] 0 0
Lille
Country [24] 0 0
France
State/province [24] 0 0
Limoges
Country [25] 0 0
France
State/province [25] 0 0
Paris
Country [26] 0 0
France
State/province [26] 0 0
PAU
Country [27] 0 0
France
State/province [27] 0 0
Toulouse
Country [28] 0 0
France
State/province [28] 0 0
Vandoeuvre-les-nancy
Country [29] 0 0
Germany
State/province [29] 0 0
Bad Berka
Country [30] 0 0
Germany
State/province [30] 0 0
Bochum
Country [31] 0 0
Germany
State/province [31] 0 0
Halle (Saale)
Country [32] 0 0
Germany
State/province [32] 0 0
Herne
Country [33] 0 0
Germany
State/province [33] 0 0
Neuruppin
Country [34] 0 0
Germany
State/province [34] 0 0
Villingen-Schwenningen
Country [35] 0 0
Greece
State/province [35] 0 0
Athens
Country [36] 0 0
Greece
State/province [36] 0 0
Heraklion
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Hungary
State/province [38] 0 0
Deszk
Country [39] 0 0
Hungary
State/province [39] 0 0
Nyíregyháza
Country [40] 0 0
Hungary
State/province [40] 0 0
Pecs
Country [41] 0 0
Hungary
State/province [41] 0 0
Szombathely
Country [42] 0 0
Hungary
State/province [42] 0 0
Torokbalint
Country [43] 0 0
Italy
State/province [43] 0 0
Emilia-Romagna
Country [44] 0 0
Italy
State/province [44] 0 0
Lazio
Country [45] 0 0
Italy
State/province [45] 0 0
Marche
Country [46] 0 0
Korea, Republic of
State/province [46] 0 0
Daegu
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Seoul
Country [48] 0 0
Korea, Republic of
State/province [48] 0 0
Suwon
Country [49] 0 0
Lithuania
State/province [49] 0 0
Kaunas
Country [50] 0 0
Lithuania
State/province [50] 0 0
Klaipeda
Country [51] 0 0
Lithuania
State/province [51] 0 0
Vilnius
Country [52] 0 0
Malaysia
State/province [52] 0 0
Kuala Lumpur
Country [53] 0 0
Malaysia
State/province [53] 0 0
Penang
Country [54] 0 0
Netherlands
State/province [54] 0 0
Amsterdam
Country [55] 0 0
Netherlands
State/province [55] 0 0
Heerlen
Country [56] 0 0
Netherlands
State/province [56] 0 0
Nieuwegein
Country [57] 0 0
Netherlands
State/province [57] 0 0
Vlissingen
Country [58] 0 0
New Zealand
State/province [58] 0 0
Auckland
Country [59] 0 0
New Zealand
State/province [59] 0 0
Christchurch
Country [60] 0 0
Poland
State/province [60] 0 0
Lodz
Country [61] 0 0
Poland
State/province [61] 0 0
Otwock
Country [62] 0 0
Romania
State/province [62] 0 0
Bucuresti
Country [63] 0 0
Romania
State/province [63] 0 0
Cluj Napoca
Country [64] 0 0
Romania
State/province [64] 0 0
Iasi
Country [65] 0 0
Romania
State/province [65] 0 0
Timisoara
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Arkhangelsk
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Balashikha
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Chelyabinsk
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Kazan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Kirov
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Krasnodar
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Kuzmolovo
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Moscow
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Nizhny Novgorod
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Perm
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Smolensk
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Soshi
Country [78] 0 0
Russian Federation
State/province [78] 0 0
St Petersburg
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Yaroslavl
Country [80] 0 0
Slovakia
State/province [80] 0 0
Banska Bystrica
Country [81] 0 0
Slovakia
State/province [81] 0 0
Bratislava
Country [82] 0 0
Slovakia
State/province [82] 0 0
Nitra
Country [83] 0 0
Slovakia
State/province [83] 0 0
Poprad
Country [84] 0 0
Slovenia
State/province [84] 0 0
Golnik
Country [85] 0 0
Slovenia
State/province [85] 0 0
Ljubljana
Country [86] 0 0
Slovenia
State/province [86] 0 0
Maribor
Country [87] 0 0
South Africa
State/province [87] 0 0
Durban
Country [88] 0 0
South Africa
State/province [88] 0 0
Johannesburg
Country [89] 0 0
South Africa
State/province [89] 0 0
Pretoria
Country [90] 0 0
Spain
State/province [90] 0 0
Asturias
Country [91] 0 0
Spain
State/province [91] 0 0
Cantabria
Country [92] 0 0
Spain
State/province [92] 0 0
La Coruña
Country [93] 0 0
Spain
State/province [93] 0 0
Valencia
Country [94] 0 0
Spain
State/province [94] 0 0
Zaragoza
Country [95] 0 0
Ukraine
State/province [95] 0 0
Kharkov
Country [96] 0 0
Ukraine
State/province [96] 0 0
Uzhgorod
Country [97] 0 0
Ukraine
State/province [97] 0 0
Zaporozhye
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Chelmsford
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Dundee
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Leicester
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Plymouth
Country [102] 0 0
Venezuela
State/province [102] 0 0
Caracas

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease progression or unacceptable toxicity during chemotherapy. Following 4 cycles of platinum-based chemotherapy, eligible patients will be randomized to receive either Tarceva 150mg po daily, or placebo daily. The anticipated time on study treatment is until disease progression; the target sample size is 500+ individuals.
Trial website
https://clinicaltrials.gov/study/NCT00556712
Trial related presentations / publications
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00556712